AGRX

In a report released today, Oren Livnat from H.C. Wainwright reiterated a Buy rating on Agile Therapeutics (AGRX – Research Report), with a price target of $5.00. The company's shares closed last Friday at $0.69, close to its 52-week low of $0.61. According to TipRanks.com, Livnat is a 1-star analyst with an average return of -2.1% and a 41.3% success rate. Livnat covers the Healthcare sector, focusing on stocks such as Collegium Pharmaceutical, Verrica Pharmaceuticals, and Satsuma Pharmaceuticals. Agile Therapeutics has an analyst consensus of Moderate Buy, with a price target consensus of $5.00.
https://www.tipranks.com/news/blurbs/agile-therapeutics-agrx-receives-a-buy-from-h-c-wainwright?utm_source=advfn.com&utm_medium=referral